Trials / Completed
CompletedNCT06025773
A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121
A Randomized, Open-label, 2x2 Crossover-design Clinical Trial to Evaluate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics After Oral Administration of AD-212-A or AD-2121 in Healthy Adult Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Addpharma Inc. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Accepted
Summary
Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-212-A in healthy subjects.
Detailed description
The purpose of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics and safety profiles of AD-212-A compared with AD-2121 in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lansoprazole 15 mg | AD-2121 (Lansoprazole 15 mg), Oral, Capsule |
| DRUG | Lansoprazole 15mg/Calcium carbonate 600mg | AD-212-A (Lansoprazole 15mg/Calcium carbonate 600mg), Oral, Tablet |
Timeline
- Start date
- 2023-09-15
- Primary completion
- 2024-04-19
- Completion
- 2024-04-19
- First posted
- 2023-09-06
- Last updated
- 2024-08-01
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06025773. Inclusion in this directory is not an endorsement.